Arrhythmogenic substrate elimination for safe testosterone therapy in symptomatic Brugada syndrome patients.
Gabriele NegroAntonio BoccellinoAntonio NapolanoEmanuele MicaglioŽarko ĆalovićLuigi AnastasiaGiuseppe CicontePublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
RFA can be considered as a therapeutic option in symptomatic BrS patients with a high-risk profile who cannot discontinue TRT, being essential for restoring their normal physiology or preserving their sexual identity. As testosterone use is increasing, further studies are warranted to define a standardized diagnostic and therapeutic strategy in this specific subset of BrS patients.